Millions of Americans could get a better night’s rest thanks to a new sleep apnea pill from startup Apnimed.

An estimated 80 million people in the U.S. are affected by sleep apnea, which is primarily treated with a CPAP, a clunky machine that forces air down the wearer’s throat to keep it open. But Apnimed is preparing to file for FDA approval for the first-ever nightly pill to treat the disorder, and if all goes well, it could be on the market in the first half of 2027.

And if even a small percentage of people with sleep apnea take the pill, it could be a major moneymaker for the firm.

Federal Reserve Chair Jerome Powell on Sunday said the Justice Department has opened a criminal investigation into his statements to Congress on the renovation of the central bank’s headquarters, in a move that sharply escalates the feud between the central bank’s leader and President Donald Trump. In his statement, Powell said he respects the rule of law but “this unprecedented action should be seen in the broader context of the administration’s threats and ongoing pressure.”

No longer referring to concerns about affordability as a “hoax,” Trump appears to be embracing policies to improve costs for consumers, calling for a one-year cap on credit card interest rates at 10%. Last week he promised to ban institutional investors from purchasing single-family homes, and could also soon reportedly sign an executive order to allow for penalty-free 401(k) withdrawals for down payments on housing.

Silver ended a volatile week on a high note, with its

© Forbes